Is Dr Agarwal's Eye overvalued or undervalued?

As of 31 October 2025, the valuation grade for Dr Agarwal's Eye has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 40.18, an EV to EBITDA of 16.40, and a Price to Book Value of 0.80, indicating a reasonable valuation relative to its earnings and asset base.
In comparison with peers, Dr Agarwal's Eye's PE Ratio is significantly lower than Max Healthcare's 92.62 and Apollo Hospitals' 70.17, both of which are categorized as very expensive and attractive, respectively. The PEG Ratio of 1.89 suggests that the company's growth is reasonably priced compared to its earnings growth potential. While the stock has underperformed the Sensex year-to-date with a return of -14.55% compared to the Sensex's 7.42%, its long-term performance remains strong with a 3-year return of 304.96%.